Talphera, Inc. (TLPH) Stock Price & Analysis
Talphera, Inc. (TLPH) fell 3.68% to USD 0.82 as of June 10, 2026 at 02:00 UTC, according to Nexqual real-time market data.
TLPH last closed at USD 0.85; the session ranged USD 0.79–0.86 on volume of 170,962 shares. Market capitalization is $42.33M, with a 52-week range of USD 0.38–1.57 (NCM). Source: Nexqual, June 10, 2026 at 02:00 UTC.
Key Statistics (as of June 10, 2026 at 02:00 UTC)
| Price | USD 0.82 |
|---|---|
| Change | ▼ 3.68% (down) |
| Previous Close | USD 0.85 |
| Open | USD 0.83 |
| Day Range | USD 0.79 – 0.86 |
| 52-Week Range | USD 0.38 – 1.57 |
| Volume | 170,962 shares |
| Market Cap | $42.33M |
| Exchange | NCM |
Technical Analysis (TLPH)
Nexqual's technical model rates TLPH "SELL" based on 1 bullish and 4 bearish signals across 124 daily candles, as of June 10, 2026 at 02:00 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 51.05 (neutral) |
| vs SMA50 | Above (USD 0.82) |
| MACD | -0.01 (negative) |
Analyst Ratings (TLPH)
Wall Street analysts rate TLPH "Strong Buy" based on 3 analysts, with a mean price target of USD 3.17 (range USD 3–3.5), per Nexqual as of June 10, 2026 at 02:00 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 3.17 |
| High Target | USD 3.5 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (TLPH)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -0.07 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.05 vs est -0.08 ▲ beat |
| 2025-12-31 | USD -0.06 vs est -0.08 ▲ beat |
| 2025-09-30 | USD -0.13 vs est -0.13 ▼ miss |
| 2025-06-30 | USD -0.1 vs est -0.12 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:00 UTC.
Financials & Fundamentals (TLPH)
| Total Revenue | $1,000 |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | -1451600.00% |
| Profit Margin | +0.00% |
| ROE | -118.40% |
| Debt / Equity | 35.17 |
| Current Ratio | 5.3 |
| Total Cash | $21.11M |
| Total Debt | $6.50M |
| Free Cash Flow | $-5.78M |
Source: Nexqual, June 10, 2026 at 02:00 UTC.
Financial Health Score (TLPH)
Nexqual rates Talphera, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:00 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $21M cash vs $6M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$6M, burning cash |
| Efficiency | Critical — ROE -118%, ROA -40.2% |
Ownership (TLPH)
| Insider Ownership | +21.38% |
|---|---|
| Institutional Ownership | +34.76% |
| Shares Outstanding | 51.90M |
| Float | 26.75M |
| Short % of Float | +2.16% |
Source: Nexqual, June 10, 2026 at 02:00 UTC.
Leadership (TLPH)
Talphera, Inc. is led by Vincent J. Angotti (age 57), CEO & Director, per Nexqual as of June 10, 2026 at 02:00 UTC.
| CEO & Director | Vincent J. Angotti (age 57) |
|---|---|
| Chief Financial Officer | Raffi Mark Asadorian (age 56) |
Major Backers & Investors (TLPH)
Notable institutional backers of Talphera, Inc. include AIGH Capital Management LLC, Rock Springs Capital Management, LP, Nantahala Capital Management, LLC, according to Nexqual as of June 10, 2026 at 02:00 UTC.
Active Investors
| Investor | Stake |
|---|---|
| AIGH Capital Management LLC | 8.98% |
| Rock Springs Capital Management, LP | 6.92% |
| Nantahala Capital Management, LLC | 6.73% |
| Rosalind Advisors, Inc. | 6.46% |
| Bleichroeder LP | 2.52% |
| Cantor Fitzgerald, L.P. | 1.71% |
| Empery Asset Management, LP | 1.14% |
| Caption Management, LLC | 1.08% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.7% |
Source: Nexqual, June 10, 2026 at 02:00 UTC.
From Talphera, Inc.'s Latest SEC 10-K Filing (filed 2026-03-23)
Key Strengths & Strategy (as disclosed to the SEC)
- Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings.
- The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.
- It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VSTM | Verastem, Inc. | USD 3.82 | ▲ 2.96% |
| VTVT | vTv Therapeutics Inc. | USD 31.77 | ▼ 1.15% |
| TNXP | Tonix Pharmaceuticals Holding C | USD 11.46 | ▲ 3.52% |
| BLRX | BioLineRx Ltd. | USD 3.21 | ▼ 0.62% |
| OGEN | Oragenics Inc. | USD 0.6 | ▲ 1.69% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:00 UTC. This page is informational and not investment advice.